Interleukin-6: An angiogenic target in solid tumours

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 1, 2014, Pages 129-139

  Middleton, Kathryn ^a   Jones, Joanna ^a   Lwin, Zarnie ^a   Coward, Jermaine I G ^a,b,c  

^a MATER ADULT HOSPITAL   (Australia)

^b TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Angiogenesis; Bevacizumab; HIF 1 ; IL 6; Siltuximab; STAT3; Sunitinib; VEGF

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 6; SILTUXIMAB; VASCULOTROPIN; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ANGIOGENESIS INHIBITOR; CABOZANTINIB; CEDIRANIB; SUNITINIB;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CHEMORADIOTHERAPY; COLORECTAL CANCER; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SOLID TUMOR; STOMACH CANCER; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG MECHANISM; MONOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; RECTUM CANCER; SALVAGE THERAPY;

ANGIOGENESIS; BEVACIZUMAB; HIF-1Α; IL-6; SILTUXIMAB; STAT3; SUNITINIB; VEGF;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INTERLEUKIN-6; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TREATMENT OUTCOME;

EID: 84890887490     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.08.004     Document Type: Review

References (120)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
2. Guo Y., Xu F., Lu T., Duan Z., Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012, 38:904-910.
3. Jones S.A., Scheller J., Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011, 121:3375-3383.
4. Horiuchi S., Koyanagi Y., Zhou Y., et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol 1994, 24:1945-1948.
5. Mullberg J., Schooltink H., Stoyan T., et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993, 23:473-480.
6. Montero-Julian F.A., Brailly H., Sautes C., et al. Characterization of soluble gp130 released by melanoma cell lines: a polyvalent antagonist of cytokines from the interleukin 6 family. Clin Cancer Res 1997, 3:1443-1451.
7. Jones S.A., Horiuchi S., Topley N., Yamamoto N., Fuller G.M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001, 15:43-58.
8. Scheller J., Ohnesorge N., Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006, 63:321-329.
9. Murakami-Mori K., Taga T., Kishimoto T., Nakamura S. The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth. Int Immunol 1996, 8:595-602.
10. Muller-Newen G., Kuster A., Hemmann U., et al. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 1998, 161:6347-6355.
11. Garbers C., Thaiss W., Jones G.W., et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem 2011, 286:42959-42970.
12. Muller-Newen G. The cytokine receptor gp130: faithfully promiscuous. Sci STKE 2003, 2003:PE40.
13. Autissier P., De Vos J., Liautard J., et al. Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb. Int Immunol 1998, 10:1881-1889.
14. Hirano T., Nakajima K., Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev 1997, 8:241-252.
15. Santer F.R., Malinowska K., Culig Z., Cavarretta I.T. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 2010, 17:241-253.
16. Suchi K., Fujiwara H., Okamura S., et al. Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res 2011, 31:67-75.
17. Trikha M., Corringham R., Klein B., Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003, 9:4653-4665.
18. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
19. Carmeliet P. Developmental biology. Controlling the cellular brakes. Nature 1999, 401:657-658.
20. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
21. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000, 21:505-515.
22. Patan S., Munn L.L., Jain R.K. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res 1996, 51:260-272.
23. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
24. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
25. Shibuya M., Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006, 312:549-560.
26. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
27. Mole D.R., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life 2001, 52:43-47.
28. Maxwell P.H., Ratcliffe P.J. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 2002, 13:29-37.
29. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
30. Xu Q., Briggs J., Park S., et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005, 24:5552-5560.
31. Niu G., Wright K.L., Huang M., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008.
32. Cohen T., Nahari D., Cerem L.W., Neufeld G., Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271:736-741.
33. Anglesio M.S., George J., Kulbe H., et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011, 17:2538-2548.
34. Holzinger C., Weissinger E., Zuckermann A., et al. Effects of interleukin-1, -2, -4 -6, interferon-gamma and granulocyte/macrophage colony stimulating factor on human vascular endothelial cells. Immunol Lett 1993, 35:109-117.
35. Fan Y., Ye J., Shen F., et al. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab 2008, 28:90-98.
36. Jee S.H., Chu C.Y., Chiu H.C., et al. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol 2004, 123:1169-1175.
37. Wang Z., Newman W.H. Smooth muscle cell migration stimulated by interleukin 6 is associated with cytoskeletal reorganization. J Surg Res 2003, 111:261-266.
38. Roth M., Nauck M., Tamm M., Perruchoud A.P., Ziesche R., Block L.H. Intracellular interleukin 6 mediates platelet-derived growth factor-induced proliferation of nontransformed cells. Proc Natl Acad Sci USA 1995, 92:1312-1316.
39. Loganadane L.D., Berge N., Legrand C., Fauvel-Lafeve F. Endothelial cell proliferation regulated by cytokines modulates thrombospondin-1 secretion into the subendothelium. Cytokine 1997, 9:740-746.
40. Zhang L., Luo L.M., Xia H., Zhuang L.Q., Tong W.C., Wen J.X. Inhibitory effects of endostatin on interleukin-6 and interleukin-8 release by human umbilical vein endothelial cells. Di Yi Jun Yi Da Xue Xue Bao 2002, 22:54-56.
41. Sainson R.C., Harris A.L. Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis 2008, 11:41-51.
42. Sansone P., Storci G., Tavolari S., et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007, 117:3988-4002.
43. Coward J., Kulbe H., Chakravarty P., et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011, 17:6083-6096.
44. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
45. Perren T.J., Swart A.M., Pfisterer J., et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
46. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
47. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
48. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
49. Waldner M.J., Foersch S., Neurath M.F. Interleukin-6 - a key regulator of colorectal cancer development. Int J Biol Sci 2012, 8:1248-1253.
50. Chung Y.C., Chang Y.F. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003, 83:222-226.
51. Knupfer H., Preiss R. Serum interleukin-6 levels in colorectal cancer patients - a summary of published results. Int J Colorectal Dis 2010, 25:135-140.
52. Komoda H., Tanaka Y., Honda M., Matsuo Y., Hazama K., Takao T. Interleukin-6 levels in colorectal cancer tissues. World J Surg 1998, 22:895-898.
53. Grivennikov S., Karin E., Terzic J., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
54. Becker C., Fantini M.C., Schramm C., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501.
55. Eldesoky A., Shouma A., Mosaad Y., Elhawary A. Clinical relevance of serum vascular endothelial growth factor and interleukin-6 in patients with colorectal cancer. Saudi J Gastroenterol 2011, 17:170-173.
56. Willett C.G., Duda D.G., di Tomaso E., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009, 27:3020-3026.
57. Karst A.M., Gao K., Nelson C.C., Li G. Nuclear factor kappa B subunit p50 promotes melanoma angiogenesis by upregulating interleukin-6 expression. Int J Cancer 2009, 124:494-501.
58. Kim H.K., Song K.S., Park Y.S., et al. Elevated levels of circulating platelet microparticles, VEGF IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003, 39:184-191.
59. Ashizawa T., Okada R., Suzuki Y., et al. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005, 8:124-131.
60. Kim D.K., Oh S.Y., Kwon H.C., et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009, 9:155.
61. Liao W.C., Lin J.T., Wu C.Y., et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res 2008, 14:428-434.
62. Kai H., Kitadai Y., Kodama M., et al. Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res 2005, 25:709-713.
63. Huang S.P., Wu M.S., Shun C.T., et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 2004, 11:517-527.
64. Ebrahimi B., Tucker S.L., Li D., Abbruzzese J.L., Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004, 101:2727-2736.
65. Feurino L.W., Zhang Y., Bharadwaj U., et al. IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol Ther 2007, 6:1096-1100.
66. Boreddy S.R., Sahu R.P., Srivastava S.K. Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-alpha/VEGF/Rho-GTPases: pivotal role of STAT-3. PLoS ONE 2011, 6:e25799.
67. Bao B., Ali S., Ahmad A., et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS ONE 2012, 7:e50165.
68. Jang J.W., Oh B.S., Kwon J.H., et al. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine 2012, 60:686-693.
69. Nakagawa H., Maeda S., Yoshida H., et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 2009, 125:2264-2269.
70. Yang X., Liang L., Zhang X.F., et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology 2013, 58:158-170.
71. Riehle K.J., Campbell J.S., McMahan R.S., et al. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J Exp Med 2008, 205:91-103.
72. Zhu A.X., Sahani D.V., Duda D.G., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27:3027-3035.
73. Coward J.I., Kulbe H. The role of interleukin-6 in gynaecological malignancies. Cytokine Growth Factor Rev 2012, 23:333-342.
74. Wei L.H., Kuo M.L., Chen C.A., et al. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol 2001, 82:49-56.
75. Wei L.H., Kuo M.L., Chen C.A., et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-1527.
76. Lo C.W., Chen M.W., Hsiao M., et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 2011, 71:424-434.
77. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005, 65:10794-10800.
78. Kulbe H., Chakravarty P., Leinster D.A., et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 2012, 72:66-75.
79. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008, 66:1-9.
80. Duluc D., Delneste Y., Tan F., et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007, 110:4319-4330.
81. Kato T., Furumoto H., Ogura T., et al. Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 2001, 282:735-738.
82. Hata T., Takahashi M., Hida S., et al. Critical role of Th17 cells in inflammation and neovascularization after ischaemia. Cardiovasc Res 2011, 90:364-372.
83. Wani A.A., Jafarnejad S.M., Zhou J., Li G. Integrin-linked kinase regulates melanoma angiogenesis by activating NF-kappaB/interleukin-6 signaling pathway. Oncogene 2011, 30:2778-2788.
84. Li J., Cheng Y., Tai D., Martinka M., Welch D.R., Li G. Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis. Oncogene 2011, 30:896-906.
85. Culig Z., Bartsch G., Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 2002, 197:231-238.
86. Borsellino N., Bonavida B., Ciliberto G., Toniatti C., Travali S., D'Alessandro N. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 1999, 85:134-144.
87. Cavarretta I.T., Neuwirt H., Untergasser G., et al. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 2007, 26:2822-2832.
88. Domingo-Domenech J., Oliva C., Rovira A., et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 2006, 12:5578-5586.
89. Giri D., Ozen M., Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001, 159:2159-2165.
90. Wang X., Lee S.O., Xia S., et al. Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGFbeta→MMP9 signals. Mol Cancer Ther 2013, 12:1026-1037.
91. Wu C.T., Hsieh C.C., Lin C.C., Chen W.C., Hong J.H., Chen M.F. Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med (Berl) 2012, 90:1343-1355.
92. Ben Jemaa A., Sallami S., Ramarli D., Colombatti M., Oueslati R. The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells. Inflammation 2013, 36:643-650.
93. Wang J., Sun Y., Song W., Nor J.E., Wang C.Y., Taichman R.S. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal 2005, 17:1578-1592.
94. Hudes G., Tagawa S.T., Whang Y.E., et al. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 2013, 31:669-676.
95. Fizazi K., De Bono J.S., Flechon A., et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012, 48:85-93.
96. Blay J.Y., Negrier S., Combaret V., et al. Analysis of changes in serum levels of TNF IL-1 and IL-6 during administration of IL-2. Correlation with clinical response to treatment. Bull Cancer 1992, 79:55-65.
97. Negrier S., Perol D., Menetrier-Caux C., et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. J Clin Oncol 2004, 22:2371-2378.
98. Blay J.Y., Negrier S., Combaret V., et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992, 52:3317-3322.
99. Fumagalli L., Lissoni P., Di Felice G., et al. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer 1999, 80:407-411.
100. Rossi J.F., Negrier S., James N.D., et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010, 103:1154-1162.
101. Porta C., Paglino C., Imarisio I., et al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 2013, 84:115-122.
102. Weissenberger J., Loeffler S., Kappeler A., et al. IL-6 is required for glioma development in a mouse model. Oncogene 2004, 23:3308-3316.
103. Liu Q., Li G., Li R., et al. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol 2010, 100:165-176.
104. Pelloski C.E., Ballman K.V., Furth A.F., et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007, 25:2288-2294.
105. Saidi A., Hagedorn M., Allain N., et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer 2009, 125:1054-1064.
106. Jin X., Kim S.H., Jeon H.M., et al. Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling. Brain 2012, 135:1055-1069.
107. Piao Y., Liang J., Holmes L., et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 2012, 14:1379-1392.
108. Sullivan N.J., Sasser A.K., Axel A.E., et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28:2940-2947.
109. de Groot J., Liang J., Kong L.Y., et al. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget 2012, 3:1036-1048.
110. Jahangiri A., De Lay M., Miller L.M., et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 2013, 19:1773-1783.
111. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
112. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
113. Song S., Ewald A.J., Stallcup W., Werb Z., Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005, 7:870-879.
114. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-78.
115. Bunt S.K., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006, 176:284-290.
116. Yang L., DeBusk L.M., Fukuda K., et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421.
117. Petit I., Jin D., Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007, 28:299-307.
118. Ceradini D.J., Kulkarni A.R., Callaghan M.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10:858-864.
119. De Falco E., Porcelli D., Torella A.R., et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004, 104:3472-3482.
120. Mizukami Y., Jo W.S., Duerr E.M., et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005, 11:992-997.